問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Chi Mei Hospital, Liouying

  • 0

    Total Beds

  • 0

    Total Doctors

  • pidb_editor
  • 736Tainan CityTainan Liouying

Recruiting Trial

140Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

293Cases

2021-09-01 - 2027-12-31

Phase II

Active
A Phase II Study to Evaluate the Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma (HCC) Patients After Curative Treatment

  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    ATL

Participate Sites
14Sites

Not yet recruiting5Sites

Recruiting9Sites

2020-07-20 - 2029-05-26

Phase III

Active
A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis (TRANSFORM-2)

  • Condition/Disease

    Myelofibrosis (MF)

  • Test Drug

    Navitoclax

Participate Sites
8Sites

Not yet recruiting4Sites

Recruiting4Sites

2024-11-01 - 2029-08-31

Phase III

Active
AndroMETa-CRC-064: An Open Label, Randomized, Controlled, Global Phase 3 Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to LONSURF (Trifluridine and Tipiracil) Plus Bevacizumab in Subjects With Refractory Metastatic Colorectal Cancer Expressing c-Met Protein Level Above a Defined Cutoff

  • Condition/Disease

    Metastatic Colorectal Cancer

  • Test Drug

    N/A

Participate Sites
10Sites

Recruiting10Sites

2020-08-01 - 2028-09-30

Phase III

Completed
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Of Navitoclax In Combination With Ruxolitinib Versus Ruxolitinib In Subjects With Myelofibrosis (TRANSFORM-1)

  • Condition/Disease

    Myelofibrosis (MF)

  • Test Drug

    Navitoclax

Participate Sites
6Sites

Not yet recruiting4Sites

Recruiting2Sites

2017-06-01 - 2026-08-31

Phase III

Completed
A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Venetoclax Co-Administered With Low Dose Cytarabine Versus Low Dose Cytarabine in Treatment Naïve Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

  • Condition/Disease

    Acute Myeloid Leukemia

  • Test Drug

    Venetoclax (ABT-199/GDC-0199)

Participate Sites
5Sites

Terminated4Sites

2025-01-01 - 2029-12-12

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting12Sites

2019-01-01 - 2030-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Recruiting13Sites

2024-04-29 - 2027-03-01

Phase II

Active
Phase II Trial of LP-300 in Combination With Carboplatin and Pemetrexed in Never Smoker Patients With Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment With Tyrosine Kinase Inhibitors (The HARMONIC Study)

  • Condition/Disease

    Adenocarcinoma of Lung 、Carcinoma, Non-Small-Cell Lung

  • Test Drug

    溶液劑

Participate Sites
5Sites

Recruiting5Sites

2023-10-31 - 2027-08-31

Phase III

Active
A Phase III, Multicenter, Randomized, Open-label Trial to Evaluate the Safety and Efficacy of Systemic Therapy With Regorafenib and Pembrolizumab Versus Locoregional Therapy With Transarterial Chemoembolization or Transarterial Radioembolization, for the First-line Treatment of Intermediate-stage Hepatocellular Carcinoma With Beyond Up-to-7 Criteria

  • Condition/Disease

    Carcinoma, Hepatocellular

  • Test Drug

    Regorafenib Keytruda injection/Keytruda

Participate Sites
8Sites

Not yet recruiting7Sites

Recruiting1Sites

2021-12-30 - 2025-12-31

Others

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

1 3 4 5 6 7 30
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB